AstraZeneca's respiratory team acknowledges its latest setback, trial flops
AstraZeneca’s respiratory R&D group has another setback to report.
The pharma giant’s partners at Dynavax Technologies $DVAX filed a statement with the SEC today noting that the research team at AstraZeneca informed them that their Phase IIa trial of the TLR9 agonist AZD1419 had flopped.
There aren’t a lot of details. Dynavax wrote:
AstraZeneca will now review the full data before deciding on the next steps for the AZD1419 program. The data will be presented at a future medical meeting.
Just a few weeks ago AstraZeneca posted mixed detailed results for its PT010 for COPD. And that arrived just days after AstraZeneca was forced to explain that its drug Bevespi Aerosphere (glycopyrronium/formoterol fumarate) couldn’t beat out GSK’s Anoro (umeclidinium/vilanterol) on peak forced expiratory volume in one second (FEV1). Measuring trough FEV1, the other co-primary endpoint in the study, AstraZeneca’s inhaler performed worse.
AstraZeneca has had much greater success in oncology, but needs to perform in all of its core R&D areas if it wants to achieve a complete turnaround, as promised by CEO Pascal Soriot.